https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-10-31 / Curr Probl Cancer 2018;42(1):49-58
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-10-31 / Curr Probl Cancer 2018;42(1):49-582017-10-31 00:00:002017-10-31 00:00:00Immunotherapy as a treatment for biliary tract cancers: A review of approaches with an eye to the future
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-10-20 / Biochem. Biophys. Res. Commun. 2017 12;494(1-2):13-19
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-10-20 / Biochem. Biophys. Res. Commun. 2017 12;494(1-2):13-192017-10-20 00:00:002019-02-15 08:52:23MtHsp70-CLIC1-pulsed dendritic cells enhance the immune response against ovarian cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-10-19 / Eur Urol Focus 2018 04;4(3):442-454
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-10-19 / Eur Urol Focus 2018 04;4(3):442-4542017-10-19 00:00:002022-09-27 09:05:10Current and Future Applications of Novel Immunotherapies in Urological Oncology: A Critical Review of the Literature
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-10-01 / Ann Transl Med 2017 Oct;5(19):386
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-10-01 / Ann Transl Med 2017 Oct;5(19):3862017-10-01 00:00:002019-02-15 08:49:52Dendritic cell therapy in melanoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-10-01 / Am J Cancer Res 2017;7(10):2091-2102
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-10-01 / Am J Cancer Res 2017;7(10):2091-21022017-10-01 00:00:002019-02-15 08:47:56Dendritic cells based immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-09-23 / Cancer Lett. 2017 12;411:182-190
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-09-23 / Cancer Lett. 2017 12;411:182-1902017-09-23 00:00:002019-02-15 08:46:13Co-delivery of tumor-derived exosomes with alpha-galactosylceramide on dendritic cell-based immunotherapy for glioblastoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-09-21 / Int. Immunopharmacol. 2017 Nov;52:197-202
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-09-21 / Int. Immunopharmacol. 2017 Nov;52:197-2022017-09-21 00:00:002019-02-15 08:45:45Increased cycles of DC/CIK immunotherapy decreases frequency of Tregs in patients with resected NSCLC
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-09-12 / Clin. Immunol. 2017 10;183:181-190
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-09-12 / Clin. Immunol. 2017 10;183:181-1902017-09-12 00:00:002019-02-15 08:45:19Hematologic neoplasms: Dendritic cells vaccines in motion
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-09-01 / G Chir 2017 Sep-Oct;37(5):225-235
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-09-01 / G Chir 2017 Sep-Oct;37(5):225-2352017-09-01 00:00:002019-02-15 08:51:59Prostate cancer immunotherapy, particularly in combination with androgen deprivation or radiation treatment. Customized pharmacogenomic approaches to overcome immunotherapy cancer resistance
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-08-22 / Blood 2017 10;130(15):1713-1721
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-08-22 / Blood 2017 10;130(15):1713-17212017-08-22 00:00:002019-02-15 08:32:49Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia
